Trial Profile
A Phase II Study in Adults With Rheumatoid Arthritis Receiving TNF-alpha-inhibitor Therapy to Assess the Immunogenicity and Safety of Trivalent Inactivated Vaccine (TIV) and High Dose Trivalent Inactivated Vaccine (High-Dose TIV) Administered at Two Dosage Levels.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary) ; Influenza A virus vaccine-H1N1; Influenza A virus vaccine-H3N2; Influenza B virus vaccine
- Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza B virus infections; Influenza virus infections
- Focus Pharmacodynamics
- 12 Apr 2020 Primary endpoint (Number of RA Participants in the 2012-2013 Season Who Achieved Seroconversion at Day 21 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received) has not been met, according to results published in the Vaccine
- 12 Apr 2020 Primary endpoint (Number of RA Participants in the 2011-2012 Season Who Achieved Seroconversion at Day 21 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant Received) has not been met, according to results published in the Vaccine
- 12 Apr 2020 Results published in the Vaccine